Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Treating obesity by quelling inflammation in the brain

How NLRP3 inhibitors could extend durability and enhance CV benefits over GLP-1 therapies alone

By Stephen Hansen, Director of Biopharma Intelligence
March 18, 2024 10:40 PM UTC

Preclinical data suggest NLRP3 could be an important new target for treating obesity. Among the benefits could be oral dosing with fewer side effects than GLP-1s and an improved cardioprotective profile. But investors shouldn’t expect to see efficacy as quickly for the anti-inflammatory mechanism as observed with incretin-based therapies.

The NLRP3 inflammasome has been implicated as a driver of pathology in a variety of diseases, ranging from cancer to asthma, heart disease and metabolic-associated steatohepatitis (MASH)...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Nodthera Ltd.

Novo Nordisk A/S

Ventus Therapeutics Inc.

Ventyx Biosciences Inc.